CA2615560A1 - Compositions and methods to control angiogenesis with cupredoxins - Google Patents

Compositions and methods to control angiogenesis with cupredoxins Download PDF

Info

Publication number: CA2615560A1
Authority: CA; Canada
Prior art keywords: cupredoxin; peptide; cells; angiogenesis; residues
Prior art date: 2005-07-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002615560A

Other languages

English (en)

French (fr)

Inventor

Rajeshwari Mehta

Brad Taylor

Tohru Yamada

Craig Beattie

Tapas Das Gupta

Ananda Chakrabarty

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Illinois System

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-07-19

Filing date

2006-07-19

Publication date

2007-03-01

2005-10-06 Priority claimed from US11/244,105 external-priority patent/US7691383B2/en

2006-05-19 Priority claimed from US11/436,592 external-priority patent/US7381701B2/en

2006-07-19 Application filed by Individual filed Critical Individual

2007-03-01 Publication of CA2615560A1 publication Critical patent/CA2615560A1/en

Status Abandoned legal-status Critical Current

Links

230000033115 angiogenesis Effects 0.000 title claims abstract description 95
239000000203 mixture Substances 0.000 title claims abstract description 56
238000000034 method Methods 0.000 title claims description 58
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 155
108010092351 cupredoxin Proteins 0.000 claims abstract description 127
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 54
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 29
210000004962 mammalian cell Anatomy 0.000 claims abstract description 18
210000004027 cell Anatomy 0.000 claims description 154
108010007337 Azurin Proteins 0.000 claims description 63
125000003275 alpha amino acid group Chemical group 0.000 claims description 61
206010028980 Neoplasm Diseases 0.000 claims description 54
201000011510 cancer Diseases 0.000 claims description 30
239000003814 drug Substances 0.000 claims description 30
229940079593 drug Drugs 0.000 claims description 25
108090000051 Plastocyanin Proteins 0.000 claims description 19
108090000035 Pseudoazurin Proteins 0.000 claims description 19
238000001990 intravenous administration Methods 0.000 claims description 14
201000001441 melanoma Diseases 0.000 claims description 13
101900113211 Pseudomonas aeruginosa Azurin Proteins 0.000 claims description 11
238000002347 injection Methods 0.000 claims description 11
239000007924 injection Substances 0.000 claims description 11
210000000481 breast Anatomy 0.000 claims description 10
206010039073 rheumatoid arthritis Diseases 0.000 claims description 9
108010086158 rusticyanin Proteins 0.000 claims description 9
206010003571 Astrocytoma Diseases 0.000 claims description 8
206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
239000002246 antineoplastic agent Substances 0.000 claims description 8
208000005017 glioblastoma Diseases 0.000 claims description 8
210000000496 pancreas Anatomy 0.000 claims description 8
241000589517 Pseudomonas aeruginosa Species 0.000 claims description 7
239000013604 expression vector Substances 0.000 claims description 7
241001673062 Achromobacter xylosoxidans Species 0.000 claims description 6
241000588813 Alcaligenes faecalis Species 0.000 claims description 6
241000588779 Bordetella bronchiseptica Species 0.000 claims description 6
241000588650 Neisseria meningitidis Species 0.000 claims description 6
201000004681 Psoriasis Diseases 0.000 claims description 6
229940005347 alcaligenes faecalis Drugs 0.000 claims description 6
229940041181 antineoplastic drug Drugs 0.000 claims description 6
238000010253 intravenous injection Methods 0.000 claims description 6
241000204362 Xylella fastidiosa Species 0.000 claims description 5
239000003937 drug carrier Substances 0.000 claims description 5
208000002780 macular degeneration Diseases 0.000 claims description 5
241000588652 Neisseria gonorrhoeae Species 0.000 claims description 4
241000607272 Vibrio parahaemolyticus Species 0.000 claims description 4
239000000829 suppository Substances 0.000 claims description 4
238000011200 topical administration Methods 0.000 claims description 4
241001646398 Pseudomonas chlororaphis Species 0.000 claims description 3
241000589540 Pseudomonas fluorescens Species 0.000 claims description 3
230000003356 anti-rheumatic effect Effects 0.000 claims description 3
229940030999 antipsoriatics Drugs 0.000 claims description 3
210000004072 lung Anatomy 0.000 claims description 3
238000010254 subcutaneous injection Methods 0.000 claims description 3
230000003178 anti-diabetic effect Effects 0.000 claims description 2
239000003472 antidiabetic agent Substances 0.000 claims description 2
210000005260 human cell Anatomy 0.000 claims description 2
238000010255 intramuscular injection Methods 0.000 claims description 2
239000007927 intramuscular injection Substances 0.000 claims description 2
239000007929 subcutaneous injection Substances 0.000 claims description 2
241000589342 Methylomonas sp. Species 0.000 claims 2
241001465754 Metazoa Species 0.000 abstract description 20
230000005748 tumor development Effects 0.000 abstract description 9
230000001575 pathological effect Effects 0.000 abstract description 7
208000024891 symptom Diseases 0.000 abstract description 7
108090000623 proteins and genes Proteins 0.000 description 53
235000018102 proteins Nutrition 0.000 description 51
102000004169 proteins and genes Human genes 0.000 description 49
235000001014 amino acid Nutrition 0.000 description 41
150000001413 amino acids Chemical class 0.000 description 40
230000000694 effects Effects 0.000 description 25
229920001184 polypeptide Polymers 0.000 description 25
238000011282 treatment Methods 0.000 description 22
230000015572 biosynthetic process Effects 0.000 description 21
150000001875 compounds Chemical class 0.000 description 19
-1 s-(3 Chemical class 0.000 description 18
238000006467 substitution reaction Methods 0.000 description 18
239000010949 copper Substances 0.000 description 16
230000012010 growth Effects 0.000 description 15
108010082117 matrigel Proteins 0.000 description 14
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 13
108020004414 DNA Proteins 0.000 description 13
229910052802 copper Inorganic materials 0.000 description 13
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 12
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 12
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 12
102000007469 Actins Human genes 0.000 description 11
108010085238 Actins Proteins 0.000 description 11
102000001392 Wiskott Aldrich Syndrome protein Human genes 0.000 description 11
108010093528 Wiskott Aldrich Syndrome protein Proteins 0.000 description 11
125000000539 amino acid group Chemical group 0.000 description 11
239000000243 solution Substances 0.000 description 11
240000008067 Cucumis sativus Species 0.000 description 10
235000010799 Cucumis sativus var sativus Nutrition 0.000 description 10
101710093642 Stellacyanin Proteins 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
241000124008 Mammalia Species 0.000 description 9
101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 9
241000192731 Chloroflexus aurantiacus Species 0.000 description 8
239000003795 chemical substances by application Substances 0.000 description 8
210000002889 endothelial cell Anatomy 0.000 description 8
230000006870 function Effects 0.000 description 8
239000000463 material Substances 0.000 description 8
239000013598 vector Substances 0.000 description 8
102000018546 Paxillin Human genes 0.000 description 7
ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 7
102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 7
239000000969 carrier Substances 0.000 description 7
230000002209 hydrophobic effect Effects 0.000 description 7
230000002401 inhibitory effect Effects 0.000 description 7
239000003446 ligand Substances 0.000 description 7
230000004807 localization Effects 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 7
230000027756 respiratory electron transport chain Effects 0.000 description 7
239000004215 Carbon black (E152) Substances 0.000 description 6
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
102000003970 Vinculin Human genes 0.000 description 6
108090000384 Vinculin Proteins 0.000 description 6
230000003527 anti-angiogenesis Effects 0.000 description 6
238000007385 chemical modification Methods 0.000 description 6
230000007423 decrease Effects 0.000 description 6
239000000835 fiber Substances 0.000 description 6
239000001963 growth medium Substances 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
238000013508 migration Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
239000012109 Alexa Fluor 568 Substances 0.000 description 5
241000196324 Embryophyta Species 0.000 description 5
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
241000530268 Lycaena heteronea Species 0.000 description 5
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
241000219000 Populus Species 0.000 description 5
208000000208 Wet Macular Degeneration Diseases 0.000 description 5
206010064930 age-related macular degeneration Diseases 0.000 description 5
210000004204 blood vessel Anatomy 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
230000014509 gene expression Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
230000001939 inductive effect Effects 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
229960000485 methotrexate Drugs 0.000 description 5
230000005012 migration Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
241000282412 Homo Species 0.000 description 4
201000006165 Kuhnt-Junius degeneration Diseases 0.000 description 4
206010058467 Lung neoplasm malignant Diseases 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
101710172711 Structural protein Proteins 0.000 description 4
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
241000607598 Vibrio Species 0.000 description 4
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 4
230000001580 bacterial effect Effects 0.000 description 4
230000004071 biological effect Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
239000002775 capsule Substances 0.000 description 4
RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 4
210000000170 cell membrane Anatomy 0.000 description 4
230000012292 cell migration Effects 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
239000003153 chemical reaction reagent Substances 0.000 description 4
239000013078 crystal Substances 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
239000008121 dextrose Substances 0.000 description 4
239000012530 fluid Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
229930195733 hydrocarbon Natural products 0.000 description 4
150000002430 hydrocarbons Chemical class 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
201000005202 lung cancer Diseases 0.000 description 4
208000020816 lung neoplasm Diseases 0.000 description 4
238000010232 migration assay Methods 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
239000000843 powder Substances 0.000 description 4
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
230000008569 process Effects 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
241000195585 Chlamydomonas Species 0.000 description 3
108010008165 Etanercept Proteins 0.000 description 3
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
241000588653 Neisseria Species 0.000 description 3
229930012538 Paclitaxel Natural products 0.000 description 3
108010069381 Platelet Endothelial Cell Adhesion Molecule-1 Proteins 0.000 description 3
108020004459 Small interfering RNA Proteins 0.000 description 3
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
150000001336 alkenes Chemical class 0.000 description 3
239000003708 ampul Substances 0.000 description 3
230000001093 anti-cancer Effects 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
125000004429 atom Chemical group 0.000 description 3
230000037396 body weight Effects 0.000 description 3
230000005907 cancer growth Effects 0.000 description 3
239000002254 cytotoxic agent Substances 0.000 description 3
229940127089 cytotoxic agent Drugs 0.000 description 3
231100000599 cytotoxic agent Toxicity 0.000 description 3
229960002949 fluorouracil Drugs 0.000 description 3
239000012634 fragment Substances 0.000 description 3
239000000499 gel Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
230000013595 glycosylation Effects 0.000 description 3
238000006206 glycosylation reaction Methods 0.000 description 3
230000028993 immune response Effects 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
229940079322 interferon Drugs 0.000 description 3
230000003211 malignant effect Effects 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
235000006109 methionine Nutrition 0.000 description 3
229960004857 mitomycin Drugs 0.000 description 3
230000004899 motility Effects 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
230000014399 negative regulation of angiogenesis Effects 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
230000006911 nucleation Effects 0.000 description 3
238000010899 nucleation Methods 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 3
229960001592 paclitaxel Drugs 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
239000004033 plastic Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
239000003755 preservative agent Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
238000002741 site-directed mutagenesis Methods 0.000 description 3
230000019635 sulfation Effects 0.000 description 3
238000005670 sulfation reaction Methods 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
239000003826 tablet Substances 0.000 description 3
230000008685 targeting Effects 0.000 description 3
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
210000003606 umbilical vein Anatomy 0.000 description 3
108010046834 umecyanin Proteins 0.000 description 3
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
241000590022 Achromobacter cycloclastes Species 0.000 description 2
241000605222 Acidithiobacillus ferrooxidans Species 0.000 description 2
YUWPMEXLKGOSBF-GACAOOTBSA-N Anecortave acetate Chemical compound O=C1CC[C@]2(C)C3=CC[C@]4(C)[C@](C(=O)COC(=O)C)(O)CC[C@H]4[C@@H]3CCC2=C1 YUWPMEXLKGOSBF-GACAOOTBSA-N 0.000 description 2
241000219195 Arabidopsis thaliana Species 0.000 description 2
108010006654 Bleomycin Proteins 0.000 description 2
101900183285 Bordetella bronchiseptica Azurin Proteins 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
241000195493 Cryptophyta Species 0.000 description 2
JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 2
101710111428 Cucumber peeling cupredoxin Proteins 0.000 description 2
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
108010036949 Cyclosporine Proteins 0.000 description 2
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
108010092160 Dactinomycin Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
102000016621 Focal Adhesion Protein-Tyrosine Kinases Human genes 0.000 description 2
108010067715 Focal Adhesion Protein-Tyrosine Kinases Proteins 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
102000014150 Interferons Human genes 0.000 description 2
108010050904 Interferons Proteins 0.000 description 2
102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 2
108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 2
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
241001424392 Lucia limbaria Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
108050007504 Mavicyanin Proteins 0.000 description 2
KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
239000008156 Ringer's lactate solution Substances 0.000 description 2
229940123237 Taxane Drugs 0.000 description 2
108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
241000700605 Viruses Species 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
229960000473 altretamine Drugs 0.000 description 2
230000009435 amidation Effects 0.000 description 2
238000007112 amidation reaction Methods 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229960001232 anecortave Drugs 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000001772 anti-angiogenic effect Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000006227 byproduct Substances 0.000 description 2
BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
ZEWYCNBZMPELPF-UHFFFAOYSA-J calcium;potassium;sodium;2-hydroxypropanoic acid;sodium;tetrachloride Chemical compound [Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2].CC(O)C(O)=O ZEWYCNBZMPELPF-UHFFFAOYSA-J 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
229960004562 carboplatin Drugs 0.000 description 2
229940047495 celebrex Drugs 0.000 description 2
229960000590 celecoxib Drugs 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
229960004316 cisplatin Drugs 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
239000000084 colloidal system Substances 0.000 description 2
229910001431 copper ion Inorganic materials 0.000 description 2
229960000640 dactinomycin Drugs 0.000 description 2
229960000975 daunorubicin Drugs 0.000 description 2
STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
230000006735 deficit Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
239000008298 dragée Substances 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
229940073621 enbrel Drugs 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 2
229930013356 epothilone Natural products 0.000 description 2
HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 2
229960005420 etoposide Drugs 0.000 description 2
VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
229960000752 etoposide phosphate Drugs 0.000 description 2
LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000000945 filler Substances 0.000 description 2
230000004927 fusion Effects 0.000 description 2
239000007789 gas Substances 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
239000003862 glucocorticoid Substances 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
239000003102 growth factor Substances 0.000 description 2
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 2
229940048921 humira Drugs 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
210000004692 intercellular junction Anatomy 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
230000009545 invasion Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000002609 medium Substances 0.000 description 2
229960001924 melphalan Drugs 0.000 description 2
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
229960001428 mercaptopurine Drugs 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
229930182817 methionine Natural products 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
230000006320 pegylation Effects 0.000 description 2
239000008177 pharmaceutical agent Substances 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
239000006187 pill Substances 0.000 description 2
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000010076 replication Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000000523 sample Substances 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
150000003431 steroids Chemical class 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
229940037128 systemic glucocorticoids Drugs 0.000 description 2
229960001603 tamoxifen Drugs 0.000 description 2
229960001278 teniposide Drugs 0.000 description 2
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
238000011191 terminal modification Methods 0.000 description 2
239000002562 thickening agent Substances 0.000 description 2
229960003087 tioguanine Drugs 0.000 description 2
239000003558 transferase inhibitor Substances 0.000 description 2
238000013519 translation Methods 0.000 description 2
229960003048 vinblastine Drugs 0.000 description 2
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
229960004528 vincristine Drugs 0.000 description 2
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 description 1
VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
WUIABRMSWOKTOF-OYALTWQYSA-N 3-[[2-[2-[2-[[(2s,3r)-2-[[(2s,3s,4r)-4-[[(2s,3r)-2-[[6-amino-2-[(1s)-3-amino-1-[[(2s)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2r,3s,4s,5s,6s)-3-[(2r,3s,4s,5r,6r)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)ox Chemical compound OS([O-])(=O)=O.N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C WUIABRMSWOKTOF-OYALTWQYSA-N 0.000 description 1
PMATZTZNYRCHOR-KMSBSJHKSA-N 30-ethyl-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone Chemical compound CCC1NC(=O)C([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-KMSBSJHKSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 1
WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 1
230000005730 ADP ribosylation Effects 0.000 description 1
241001453369 Achromobacter denitrificans Species 0.000 description 1
241000266272 Acidithiobacillus Species 0.000 description 1
WQVFQXXBNHHPLX-ZKWXMUAHSA-N Ala-Ala-His Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O WQVFQXXBNHHPLX-ZKWXMUAHSA-N 0.000 description 1
YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
239000012099 Alexa Fluor family Substances 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
108700009603 Ambrosia artemisiifolia Amb a III Proteins 0.000 description 1
PTVGLOCPAVYPFG-CIUDSAMLSA-N Arg-Gln-Asp Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O PTVGLOCPAVYPFG-CIUDSAMLSA-N 0.000 description 1
240000003291 Armoracia rusticana Species 0.000 description 1
235000011330 Armoracia rusticana Nutrition 0.000 description 1
108010024957 Ascorbate Oxidase Proteins 0.000 description 1
PTNFNTOBUDWHNZ-GUBZILKMSA-N Asn-Arg-Met Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(O)=O PTNFNTOBUDWHNZ-GUBZILKMSA-N 0.000 description 1
LJUOLNXOWSWGKF-ACZMJKKPSA-N Asn-Asn-Glu Chemical compound C(CC(=O)O)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CC(=O)N)N LJUOLNXOWSWGKF-ACZMJKKPSA-N 0.000 description 1
KHCNTVRVAYCPQE-CIUDSAMLSA-N Asn-Lys-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O KHCNTVRVAYCPQE-CIUDSAMLSA-N 0.000 description 1
FANQWNCPNFEPGZ-WHFBIAKZSA-N Asp-Asp-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(O)=O FANQWNCPNFEPGZ-WHFBIAKZSA-N 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
101800003321 Auracyanin-B-2 Proteins 0.000 description 1
NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical class C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
PCLCDPVEEFVAAQ-UHFFFAOYSA-N BCA 1 Chemical compound CC(CO)CCCC(C)C1=CCC(C)(O)C1CC2=C(O)C(O)CCC2=O PCLCDPVEEFVAAQ-UHFFFAOYSA-N 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
108010037003 Buserelin Proteins 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
102100025277 C-X-C motif chemokine 13 Human genes 0.000 description 1
FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
241000192700 Cyanobacteria Species 0.000 description 1
241001464430 Cyanobacterium Species 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
108010075021 Cytochromes f Proteins 0.000 description 1
VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
101710088194 Dehydrogenase Proteins 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 description 1
108091006149 Electron carriers Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229940122293 Ephrin antagonist Drugs 0.000 description 1
102000006396 Ephrin-B2 Human genes 0.000 description 1
108010044090 Ephrin-B2 Proteins 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
108010029961 Filgrastim Proteins 0.000 description 1
229940123414 Folate antagonist Drugs 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
NUSWUSKZRCGFEX-FXQIFTODSA-N Glu-Glu-Cys Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CS)C(O)=O NUSWUSKZRCGFEX-FXQIFTODSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
229920002971 Heparan sulfate Polymers 0.000 description 1
238000010867 Hoechst staining Methods 0.000 description 1
101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 description 1
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 description 1
101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
IOVUXUSIGXCREV-DKIMLUQUSA-N Ile-Leu-Phe Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 IOVUXUSIGXCREV-DKIMLUQUSA-N 0.000 description 1
LRAUKBMYHHNADU-DKIMLUQUSA-N Ile-Phe-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)[C@@H](C)CC)CC1=CC=CC=C1 LRAUKBMYHHNADU-DKIMLUQUSA-N 0.000 description 1
208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
108010000817 Leuprolide Proteins 0.000 description 1
JXLYSJRDGCGARV-PJXZDTQASA-N Leurosidine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-PJXZDTQASA-N 0.000 description 1
LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
LPGWZGMPDKDHEP-GKWAKPNHSA-N Leurosine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@]6(CC)O[C@@H]6[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C LPGWZGMPDKDHEP-GKWAKPNHSA-N 0.000 description 1
HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
208000002720 Malnutrition Diseases 0.000 description 1
101710159527 Maturation protein A Proteins 0.000 description 1
101710091157 Maturation protein A2 Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
108010063312 Metalloproteins Proteins 0.000 description 1
102000010750 Metalloproteins Human genes 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
241001108454 Neisseria gonorrhoeae F62 Species 0.000 description 1
206010061309 Neoplasm progression Diseases 0.000 description 1
102100037369 Nidogen-1 Human genes 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
108010016076 Octreotide Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
108700020796 Oncogene Proteins 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
102000004316 Oxidoreductases Human genes 0.000 description 1
101150044441 PECAM1 gene Proteins 0.000 description 1
101150054473 PTK2 gene Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
108010009711 Phalloidine Proteins 0.000 description 1
244000046052 Phaseolus vulgaris Species 0.000 description 1
KIQUCMUULDXTAZ-HJOGWXRNSA-N Phe-Tyr-Tyr Chemical compound N[C@@H](Cc1ccccc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(O)=O KIQUCMUULDXTAZ-HJOGWXRNSA-N 0.000 description 1
241001453201 Phormidium laminosum Species 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
102100024028 Progonadoliberin-1 Human genes 0.000 description 1
239000004365 Protease Substances 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
241000589615 Pseudomonas syringae Species 0.000 description 1
KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
229930183496 Safracin Natural products 0.000 description 1
229930190585 Saframycin Natural products 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
241000195663 Scenedesmus Species 0.000 description 1
QMCDMHWAKMUGJE-IHRRRGAJSA-N Ser-Phe-Val Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O QMCDMHWAKMUGJE-IHRRRGAJSA-N 0.000 description 1
FZXOPYUEQGDGMS-ACZMJKKPSA-N Ser-Ser-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(O)=O FZXOPYUEQGDGMS-ACZMJKKPSA-N 0.000 description 1
DKGRNFUXVTYRAS-UBHSHLNASA-N Ser-Ser-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O DKGRNFUXVTYRAS-UBHSHLNASA-N 0.000 description 1
UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 description 1
108090000054 Syndecan-2 Proteins 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
241000605118 Thiobacillus Species 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
COYHRQWNJDJCNA-NUJDXYNKSA-N Thr-Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O COYHRQWNJDJCNA-NUJDXYNKSA-N 0.000 description 1
241000592342 Tracheophyta Species 0.000 description 1
102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
ARJASMXQBRNAGI-YESZJQIVSA-N Tyr-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC2=CC=C(C=C2)O)N ARJASMXQBRNAGI-YESZJQIVSA-N 0.000 description 1
241000196252 Ulva Species 0.000 description 1
229940122803 Vinca alkaloid Drugs 0.000 description 1
241000320125 Xylella fastidiosa 9a5c Species 0.000 description 1
229960003697 abatacept Drugs 0.000 description 1
JXLYSJRDGCGARV-KSNABSRWSA-N ac1l29ym Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-KSNABSRWSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229960002964 adalimumab Drugs 0.000 description 1
238000011374 additional therapy Methods 0.000 description 1
239000000654 additive Substances 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
229960005310 aldesleukin Drugs 0.000 description 1
108700025316 aldesleukin Proteins 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
238000005865 alkene metathesis reaction Methods 0.000 description 1
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
150000008052 alkyl sulfonates Chemical class 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
239000000956 alloy Substances 0.000 description 1
229910045601 alloy Inorganic materials 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
229960004238 anakinra Drugs 0.000 description 1
239000003098 androgen Substances 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
239000004037 angiogenesis inhibitor Substances 0.000 description 1
230000002547 anomalous effect Effects 0.000 description 1
229940045799 anthracyclines and related substance Drugs 0.000 description 1
230000002280 anti-androgenic effect Effects 0.000 description 1
229940046836 anti-estrogen Drugs 0.000 description 1
230000001833 anti-estrogenic effect Effects 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940124599 anti-inflammatory drug Drugs 0.000 description 1
230000000340 anti-metabolite Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
229940124350 antibacterial drug Drugs 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940100197 antimetabolite Drugs 0.000 description 1
239000002256 antimetabolite Substances 0.000 description 1
229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000001640 apoptogenic effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
229940059756 arava Drugs 0.000 description 1
238000003556 assay Methods 0.000 description 1
AUJRCFUBUPVWSZ-XTZHGVARSA-M auranofin Chemical compound CCP(CC)(CC)=[Au]S[C@@H]1O[C@H](COC(C)=O)[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O AUJRCFUBUPVWSZ-XTZHGVARSA-M 0.000 description 1
229960005207 auranofin Drugs 0.000 description 1
229940009100 aurothiomalate Drugs 0.000 description 1
XJHSMFDIQHVMCY-UHFFFAOYSA-M aurothiomalic acid Chemical compound OC(=O)CC(S[Au])C(O)=O XJHSMFDIQHVMCY-UHFFFAOYSA-M 0.000 description 1
229940120638 avastin Drugs 0.000 description 1
229960002170 azathioprine Drugs 0.000 description 1
150000001540 azides Chemical class 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
229960004395 bleomycin sulfate Drugs 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036770 blood supply Effects 0.000 description 1
230000015624 blood vessel development Effects 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
229960002719 buserelin Drugs 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
230000000711 cancerogenic effect Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
229930188550 carminomycin Natural products 0.000 description 1
XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
229950001725 carubicin Drugs 0.000 description 1
238000012219 cassette mutagenesis Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000030833 cell death Effects 0.000 description 1
230000011712 cell development Effects 0.000 description 1
230000032823 cell division Effects 0.000 description 1
230000004709 cell invasion Effects 0.000 description 1
230000009134 cell regulation Effects 0.000 description 1
239000000919 ceramic Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
230000009920 chelation Effects 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
229960004630 chlorambucil Drugs 0.000 description 1
JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
210000003763 chloroplast Anatomy 0.000 description 1
229960001265 ciclosporin Drugs 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000011278 co-treatment Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
239000003086 colorant Substances 0.000 description 1
LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 1
229960005527 combretastatin A-4 phosphate Drugs 0.000 description 1
WDOGQTQEKVLZIJ-WAYWQWQTSA-N combretastatin a-4 phosphate Chemical compound C1=C(OP(O)(O)=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 WDOGQTQEKVLZIJ-WAYWQWQTSA-N 0.000 description 1
238000000942 confocal micrograph Methods 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
229930182912 cyclosporin Natural products 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
239000003145 cytotoxic factor Substances 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
230000006240 deamidation Effects 0.000 description 1
230000007547 defect Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
229940027008 deltasone Drugs 0.000 description 1
238000009795 derivation Methods 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
229960002918 doxorubicin hydrochloride Drugs 0.000 description 1
235000005489 dwarf bean Nutrition 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
229940088598 enzyme Drugs 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
150000003883 epothilone derivatives Chemical class 0.000 description 1
229960001842 estramustine Drugs 0.000 description 1
FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
229960001766 estramustine phosphate sodium Drugs 0.000 description 1
IIUMCNJTGSMNRO-VVSKJQCTSA-L estramustine sodium phosphate Chemical compound [Na+].[Na+].ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)OP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 IIUMCNJTGSMNRO-VVSKJQCTSA-L 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000000328 estrogen antagonist Substances 0.000 description 1
229960000403 etanercept Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229960004177 filgrastim Drugs 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
229940043075 fluocinolone Drugs 0.000 description 1
FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
229960002074 flutamide Drugs 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
230000006251 gamma-carboxylation Effects 0.000 description 1
229960005277 gemcitabine Drugs 0.000 description 1
229960005144 gemcitabine hydrochloride Drugs 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
IRPYFWIZKIOHQN-XTZHGVARSA-N gold;[(2r,3r,4s,5r,6s)-3,4,5-triacetyloxy-6-sulfanyloxan-2-yl]methyl acetate;triethylphosphane Chemical compound [Au].CC[PH+](CC)CC.CC(=O)OC[C@H]1O[C@@H]([S-])[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1OC(C)=O IRPYFWIZKIOHQN-XTZHGVARSA-N 0.000 description 1
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 description 1
239000003979 granulating agent Substances 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
229910001385 heavy metal Inorganic materials 0.000 description 1
201000005787 hematologic cancer Diseases 0.000 description 1
208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229940125697 hormonal agent Drugs 0.000 description 1
102000058223 human VEGFA Human genes 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
229940096120 hydrea Drugs 0.000 description 1
230000005661 hydrophobic surface Effects 0.000 description 1
125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
229960004171 hydroxychloroquine Drugs 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
229960000908 idarubicin Drugs 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
230000036039 immunity Effects 0.000 description 1
239000000367 immunologic factor Substances 0.000 description 1
229940073062 imuran Drugs 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000001524 infective effect Effects 0.000 description 1
229960000598 infliximab Drugs 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
102000006495 integrins Human genes 0.000 description 1
108010044426 integrins Proteins 0.000 description 1
230000003993 interaction Effects 0.000 description 1
229940047122 interleukins Drugs 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229960000779 irinotecan hydrochloride Drugs 0.000 description 1
GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
238000006317 isomerization reaction Methods 0.000 description 1
229960005280 isotretinoin Drugs 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
229940054136 kineret Drugs 0.000 description 1
229960000681 leflunomide Drugs 0.000 description 1
235000005772 leucine Nutrition 0.000 description 1
150000002614 leucines Chemical class 0.000 description 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
229960004338 leuprorelin Drugs 0.000 description 1
229960001614 levamisole Drugs 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000002502 liposome Substances 0.000 description 1
230000007762 localization of cell Effects 0.000 description 1
229960002247 lomustine Drugs 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229940076783 lucentis Drugs 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000001071 malnutrition Effects 0.000 description 1
235000000824 malnutrition Nutrition 0.000 description 1
230000035800 maturation Effects 0.000 description 1
229960002868 mechlorethamine hydrochloride Drugs 0.000 description 1
QZIQJVCYUQZDIR-UHFFFAOYSA-N mechlorethamine hydrochloride Chemical compound Cl.ClCCN(C)CCCl QZIQJVCYUQZDIR-UHFFFAOYSA-N 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
150000002742 methionines Chemical class 0.000 description 1
FBOZXECLQNJBKD-UHFFFAOYSA-N methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-UHFFFAOYSA-N 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
239000011707 mineral Substances 0.000 description 1
CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
229960000350 mitotane Drugs 0.000 description 1
239000003068 molecular probe Substances 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
229960004866 mycophenolate mofetil Drugs 0.000 description 1
201000000050 myeloid neoplasm Diseases 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000010046 negative regulation of endothelial cell proliferation Effects 0.000 description 1
229940063121 neoral Drugs 0.000 description 1
108010008217 nidogen Proteins 0.000 description 1
238000012758 nuclear staining Methods 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
208000015380 nutritional deficiency disease Diseases 0.000 description 1
229960001494 octreotide acetate Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
239000002674 ointment Substances 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
229940035567 orencia Drugs 0.000 description 1
229920000620 organic polymer Polymers 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
230000003071 parasitic effect Effects 0.000 description 1
229960003407 pegaptanib Drugs 0.000 description 1
229960001639 penicillamine Drugs 0.000 description 1
230000000243 photosynthetic effect Effects 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
108700024913 plant stellacyanin Proteins 0.000 description 1
229940072689 plaquenil Drugs 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229910052697 platinum Inorganic materials 0.000 description 1
229960003171 plicamycin Drugs 0.000 description 1
229960001237 podophyllotoxin Drugs 0.000 description 1
YVCVYCSAAZQOJI-UHFFFAOYSA-N podophyllotoxin Natural products COC1=C(O)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YVCVYCSAAZQOJI-UHFFFAOYSA-N 0.000 description 1
239000003600 podophyllotoxin derivative Substances 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
229960000624 procarbazine Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
239000000583 progesterone congener Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
229960003876 ranibizumab Drugs 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000011514 reflex Effects 0.000 description 1
229940116176 remicade Drugs 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
208000029922 reticulum cell sarcoma Diseases 0.000 description 1
210000001525 retina Anatomy 0.000 description 1
229940061969 rheumatrex Drugs 0.000 description 1
229940063638 ridaura Drugs 0.000 description 1
229960004641 rituximab Drugs 0.000 description 1
239000005060 rubber Substances 0.000 description 1
229910052707 ruthenium Inorganic materials 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229960003440 semustine Drugs 0.000 description 1
238000002864 sequence alignment Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
230000035939 shock Effects 0.000 description 1
210000001626 skin fibroblast Anatomy 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
229950001248 squalamine Drugs 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960001052 streptozocin Drugs 0.000 description 1
ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
229960001940 sulfasalazine Drugs 0.000 description 1
NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
239000002511 suppository base Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000007755 survival signaling Effects 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
229960000977 trabectedin Drugs 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000026683 transduction Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
229960001727 tretinoin Drugs 0.000 description 1
150000004654 triazenes Chemical class 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
230000005740 tumor formation Effects 0.000 description 1
230000005751 tumor progression Effects 0.000 description 1
230000034512 ubiquitination Effects 0.000 description 1
238000010798 ubiquitination Methods 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
241001430294 unidentified retrovirus Species 0.000 description 1
230000002792 vascular Effects 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
229960004355 vindesine Drugs 0.000 description 1
UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
229960002166 vinorelbine tartrate Drugs 0.000 description 1
GBABOYUKABKIAF-IWWDSPBFSA-N vinorelbinetartrate Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC(C23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IWWDSPBFSA-N 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
238000012982 x-ray structure analysis Methods 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/415—Assays involving biological materials from specific organisms or of a specific nature from plants
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Orthopedic Medicine & Surgery (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CA002615560A 2005-07-19 2006-07-19 Compositions and methods to control angiogenesis with cupredoxins Abandoned CA2615560A1 (en)

Applications Claiming Priority (9)

Application Number	Priority Date	Filing Date	Title
US70029705P	2005-07-19	2005-07-19
US60/700,297		2005-07-19
US11/244,105 US7691383B2 (en)	2004-10-07	2005-10-06	Cupredoxin derived transport agents and methods of use thereof
US11/244,105		2005-10-06
US76474906P	2006-02-03	2006-02-03
US60/764,749		2006-02-03
US11/436,592		2006-05-19
US11/436,592 US7381701B2 (en)	2001-02-15	2006-05-19	Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
PCT/US2006/027940 WO2007024368A2 (en)	2005-07-19	2006-07-19	Compositions and methods to control angiogenesis with cupredoxins

Publications (1)

Publication Number	Publication Date
CA2615560A1 true CA2615560A1 (en)	2007-03-01

Family

ID=37772089

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002615560A Abandoned CA2615560A1 (en)	2005-07-19	2006-07-19	Compositions and methods to control angiogenesis with cupredoxins

Country Status (10)

Country	Link
EP (1)	EP1904081A4 (de)
JP (1)	JP2009502797A (de)
KR (1)	KR20080034905A (de)
AU (1)	AU2006284490A1 (de)
BR (1)	BRPI0615555A2 (de)
CA (1)	CA2615560A1 (de)
IL (1)	IL188691A0 (de)
MX (1)	MX2008000993A (de)
NO (1)	NO20080829L (de)
WO (1)	WO2007024368A2 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8158574B2 (en) *	2004-10-07	2012-04-17	Cdg Therapeutics, Inc.	Compositions and methods to prevent cancer with cupredoxins
EP2061498A4 (de) *	2006-09-14	2009-11-04	Univ Illinois	Zusammensetzungen und verfahren zur krebsvorbeugung mit cupredoxinen
JP2010511408A (ja) *	2006-12-04	2010-04-15	ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ	癌をＣｐＧリッチＤＮＡおよびキュプレドキシンで治療するための組成物および方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7491394B2 (en) *	2001-02-15	2009-02-17	The Board Of Trustees Of The University Of Illinois	Cytotoxic factors for modulating cell death
EA200700813A1 (ru) *	2004-10-07	2008-10-30	Ананда Чакрабарти	Транспортирующие вещества, производные купредоксина и способы их применения
AU2006277009A1 (en) *	2005-05-20	2007-02-15	The Board Of Trustees Of The University Of Illinois	Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
EP1882039A4 (de) *	2005-05-20	2008-08-20	Univ Illinois	Zusammensetzungen und verfahren zur behandlung von malaria mit cupredoxin und cytochrom
EP1883650A4 (de) *	2005-05-20	2009-06-10	Univ Illinois	Zusammensetzungen und verfahren zur behandlung von hiv-infektionen mit cupredoxin und cytochrom c

2006
- 2006-07-19 WO PCT/US2006/027940 patent/WO2007024368A2/en not_active Ceased
- 2006-07-19 AU AU2006284490A patent/AU2006284490A1/en not_active Abandoned
- 2006-07-19 KR KR1020087002477A patent/KR20080034905A/ko not_active Ceased
- 2006-07-19 JP JP2008522911A patent/JP2009502797A/ja active Pending
- 2006-07-19 EP EP06787787A patent/EP1904081A4/de not_active Withdrawn
- 2006-07-19 MX MX2008000993A patent/MX2008000993A/es active IP Right Grant
- 2006-07-19 CA CA002615560A patent/CA2615560A1/en not_active Abandoned
- 2006-07-19 BR BRPI0615555-3A patent/BRPI0615555A2/pt not_active IP Right Cessation
2008
- 2008-01-09 IL IL188691A patent/IL188691A0/en unknown
- 2008-02-15 NO NO20080829A patent/NO20080829L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2007024368A3 (en)	2007-10-11
JP2009502797A (ja)	2009-01-29
WO2007024368A2 (en)	2007-03-01
EP1904081A4 (de)	2008-12-03
AU2006284490A1 (en)	2007-03-01
NO20080829L (no)	2008-04-02
MX2008000993A (es)	2008-03-19
AU2006284490A8 (en)	2008-02-28
BRPI0615555A2 (pt)	2009-07-14
EP1904081A2 (de)	2008-04-02
KR20080034905A (ko)	2008-04-22
IL188691A0 (en)	2008-08-07

Legal Events

Date	Code	Title	Description
2008-04-23	EEER	Examination request
2012-02-03	FZDE	Discontinued

Publication	Publication Date	Title
US9107881B2 (en)	2015-08-18	Compositions and methods to control angiogenesis with cupredoxins
US8623816B2 (en)	2014-01-07	Compositions and methods for treating malaria with cupredoxin and cytochrome
US10421801B2 (en)	2019-09-24	Cytotoxic factors for modulating cell death
US8232244B2 (en)	2012-07-31	Compositions and methods to prevent cancer with cupredoxins
US10889621B2 (en)	2021-01-12	Compositions and methods for treating conditions related to ephrin signaling with Cupredoxins
SG174784A1 (en)	2011-10-28	Compositions and methods to prevent cancer with cupredoxins
CA2608512A1 (en)	2007-02-15	Compositions and methods for treating conditions related to ephrin signaling with cupredoxins
CA2615560A1 (en)	2007-03-01	Compositions and methods to control angiogenesis with cupredoxins
AU2010201360A1 (en)	2010-04-29	Compositions and methods for treating malaria with cupredoxin and cytochrome
CN101272800A (zh)	2008-09-24	使用铜氧还蛋白控制血管发生的组合物和方法
ZA200602126B (en)	2007-09-26	Use of polypeptides of the cupredoxin family in cancer therapy